Severe combined immunodeficiency. A model disease for molecular immunology and therapy
- PMID: 15661024
- DOI: 10.1111/j.0105-2896.2005.00223.x
Severe combined immunodeficiency. A model disease for molecular immunology and therapy
Abstract
Severe combined immunodeficiencies (SCIDs) consist of genetically determined arrest of T-cell differentiation. Ten different molecular defects have now been identified, which all lead to early death in the absence of therapy. Transplantation of allogeneic hematopoietic stem cells (HSCT) can restore T-cell development, thus saving the lives of SCID patients. In this review, the different characteristics of HSCT are discussed along with the available data regarding the long-term outcome. Transient thymopoiesis caused by an exhaustion of donor progenitor cells and possibly a progressive loss of thymus function can lead to a progressive decline in T-cell functions. The preliminary results of gene therapy show the correction of two SCID conditions. Based on the assumption that long-lasting pluripotent progenitor cells are transduced, these data suggest that gene therapy could overcome the long-term recurrence of the T-cell immunodeficiency. SCID is thus a disease model for experimental therapy in the hematopoietic system.
Similar articles
-
Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.Mol Ther. 2006 Oct;14(4):505-13. doi: 10.1016/j.ymthe.2006.06.007. Epub 2006 Aug 14. Mol Ther. 2006. PMID: 16905365
-
Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.N Engl J Med. 2002 Apr 18;346(16):1185-93. doi: 10.1056/NEJMoa012616. N Engl J Med. 2002. PMID: 11961146 Clinical Trial.
-
Gene therapy of severe combined immunodeficiencies.J Gene Med. 2001 May-Jun;3(3):201-6. doi: 10.1002/1521-2254(200105/06)3:3<201::AID-JGM195>3.0.CO;2-Z. J Gene Med. 2001. PMID: 11437325 Review.
-
Hematopoietic stem cell transplantation for severe combined immune deficiency or what the children have taught us.Immunol Allergy Clin North Am. 2010 Feb;30(1):17-30. doi: 10.1016/j.iac.2009.10.002. Immunol Allergy Clin North Am. 2010. PMID: 20113884 Review.
-
Hematopoietic stem cell transplantation for severe combined immunodeficiency diseases.Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):73-5. doi: 10.1016/j.bbmt.2007.10.017. Biol Blood Marrow Transplant. 2008. PMID: 18162224 Review.
Cited by
-
Temporal protein expression pattern in intracellular signalling cascade during T-cell activation: a computational study.J Biosci. 2015 Oct;40(4):769-89. doi: 10.1007/s12038-015-9561-1. J Biosci. 2015. PMID: 26564978
-
Use of V(D)J recombination excision circles to identify T- and B-cell defects and to monitor the treatment in primary and acquired immunodeficiencies.J Transl Med. 2013 May 9;11:119. doi: 10.1186/1479-5876-11-119. J Transl Med. 2013. PMID: 23656963 Free PMC article. Review.
-
Purified hematopoietic stem cell engraftment of rare niches corrects severe lymphoid deficiencies without host conditioning.J Exp Med. 2006 Jan 23;203(1):73-85. doi: 10.1084/jem.20051714. Epub 2005 Dec 27. J Exp Med. 2006. PMID: 16380511 Free PMC article.
-
Flow Cytometry for the Diagnosis of Primary Immunodeficiency Diseases: A Single Center Experience.Allergy Asthma Immunol Res. 2020 Mar;12(2):292-305. doi: 10.4168/aair.2020.12.2.292. Allergy Asthma Immunol Res. 2020. PMID: 32009323 Free PMC article.
-
Generation of inactivated IL2RG and RAG1 monkeys with severe combined immunodeficiency using base editing.Signal Transduct Target Ther. 2023 Sep 4;8(1):327. doi: 10.1038/s41392-023-01544-y. Signal Transduct Target Ther. 2023. PMID: 37661226 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
